AzTrials
AzTrials

AnesthesiaNCT04024904

Virtual Reality Hypnosis Distraction Utility to Improve Tolerance to Regional Anaesthesia

A study testing OncomfortTM device in people with Anesthesia, run by Erasme University Hospital at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Regional anaesthesia has many advantages but it might be a stressful and painful experience. Usually, the anesthetist administers a pharmacologic intravenous sedation to achieve patient's comfort. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Anesthesia
What is being tested?
OncomfortTM device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteBelgium
Study dates
26 Jul 2018to 30 Nov 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • undergoing elective orthopedic surgery with regional anaesthesia (peripheral nerve block), were aged ≥ 18 years

Who cannot join

  • ASA (American Society of anesthesiologists) IV, spinal anesthesia, claustrophobia, blindness, deafness, unable to complete a satisfaction survey, previously documented history of neurologic disease, lack of written informed consent, urgent surgery, allergy to a drug used within the study, ongoing pregnancy, patient's infectious isolation

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • ULB-Erasme Hospital

    Brussels, 1070

Other trials in Belgium

About this study

Official title: Virtual Reality Hypnosis Distraction Utility to Improve the Quality of Routine Procedure-related Pain During Preoperative Locoregional Anaesthesia

Regional anaesthesia has many advantages but it might be a stressful and painful experience. Usually, the anesthetist administers a pharmacologic intravenous sedation to achieve patient's comfort. Though, these medications are not benign, and disadvantages include unpredictable response, adverse effects, and interference with cooperation. The virtual reality hypnosis distraction (VRHD) could be a good non-pharmacological technique to improve patient's comfort, decrease anxiety and procedure related pain. This study is a prospective study where sixty patients scheduled for orthopedic surgery requiring regional anesthesia were randomized in three groups according to the use or not of VRHD during the regional procedure or before as a complementary premedication. The anesthetic management during the regional procedure and the surgery remained otherwise standard for each patient. The first endpoint is the proportion of patients receiving pharmacological sedation (in the VRHD groups compared to the pharmacological sedation group). .

The second endpoint is to determine if the VRHD increases the patient's satisfaction of their anaesthetic management.

The third endpoint is to study various parameters of use of this specific anaesthetic management: time required for the installation and operation time of the VRHD device; the variation of haemodynamic parameters between the separate groups; pain procedure-related and behavioural pain scale scores between the separate groups.

Read the detailed description

Background Regional anesthesia has many advantages but it might be a stressful and painful experience and the anaesthetist has to establish all the necessary measures to maintain patient's comfort and cooperation. In practice, this ideal situation may be the most challenging part of the regional anesthetic practice. Usually, the anesthetist administers a pharmacologic intravenous sedation, including opioids and benzodiazepines to achieve patient's comfort. These medications are not benign, and disadvantages include possible unpredictable response, adverse effects, and hindered cooperation.

Among the non-pharmacologic techniques which may be used to improve the patient's comfort, decrease anxiety and procedure related pain, hypnosis and virtual reality distraction are increasingly used.

In spite of the encouraging scientific and clinical findings, hypnosis for analgesia is not universally used in medical centers. Its widespread use has been limited by factors such as the advanced expertise, time and effort required by clinicians to provide hypnosis, and the commitment required by patients to engage in hypnosis. It is a challenge to make hypnosis a standard part of care in this environment.

Improvements in technologies made virtual reality (VR) distraction a unique practical tool to provide an immersive, multisensory and three-dimensional (3D) environment that creates a sense of presence which enables to modify the perception of reality and to capture a greater degree of attention. Several theories have been proposed to explain how distraction may inhibit or decrease perception of pain by capturing a greater degree of attention. The "virtual reality analgesia" (= analgesia produces by virtual reality) is a product of the attentional distraction. Hoffmann et al. explained that there is a limit to the conscious attentional resources humans have available to process large amounts of incoming information. Conscious attention is required for pain perception. Hoffmann et al. theorize that the more immersive the VR system, the more attention will be drawn into the virtual world, leaving less attention available to process nociceptive signals.

Until now, VR shows an interest in numerous clinical applications (to help treat anxiety disorders, control pain, support physical rehabilitation, and distract patients during wound care) VR technology guides the patient through the same steps used when hypnosis is induced through an interpersonal process. With attentional mechanisms as a common denominator, the attention-captivating qualities of virtual reality and the suggestion inherent in hypnosis, the potential for a synergistic effect between these modalities is significant.

Using a device which combined the advantage of VR technology and hypnosis could probably improve the patient's comfort, decrease his anxiety and procedure related pain.

The first endpoint consist in a significant minimal decrease of 50% of the requirement of IVS delivered to the patient throughout the regional performance, in comparison to the IVS group when using VRHD.

The second endpoint is to determine if VRHD increases patient's satisfaction concerning their anaesthetic management.

The third endpoint is to study various parameters of this specific anesthetic management: time required for the installation and operation time of the VRHD device; variation of haemodynamic parameters; pain procedure-related and behavioural pain scale scores.

Methods Our study is a prospective randomized study. The protocol was approved by the Independent Ethics Committee from Erasmus Hospital.

Written Informed consent was obtained from all participating subjects. Subjects were randomized by the use of a computer-generated random table. Sixty patients scheduled for orthopaedic surgery needing regional anaesthesia are randomized according to the used of VRHD during the regional procedure or before as a complementary premedication.

The patients and the anesthetist in charge of the patient were not blinded but the data collection and statistical analysis were blinded.

Anesthesia management The anesthetic management was standardized for each patient. All subjects were fasting from midnight and premedicated with 0,25-0,5 mg alprazolam per os one hour before the procedure.

During the regional block, the surgical asepsis was respected and the regional block was performed under ultrasound guidance (machine Epic or Philips…). A basic monitoring was installed (EKG (electrocardiogram), NIBP (non-invasive blood pressure), SpO2 (pulse oximetry saturation). A 18 gauge catheter was placed in a vein. To avoid hypoxemia, all patients benefited of a supplemental nasal oxygen (3l/min) if the SpO2 < 95%.

Intraoperatively, the patient was maintained under sedation or general anesthesia according to the surgical prerequisites.

In the postoperative period, standard care was provided to the patient at the postoperative care unit according the American society of anesthesiologists (ASA) recommendations.

Study protocol In the control group, the patient received the standard pharmacologic intravenous sedation before the regional anaesthesia (2 mg midazolam + 5 µg de sufentanil) without VRHD.

In the study group VRHD 1, the patient received the VHRD technique during the peripheral nerve block and received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score >3).

In the study group VRHD 2, the patient received the VHRD technique a first time before the regional procedure and a second time during the peripheral nerve block. The patient received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score >3).

Virtual reality hypnosis distraction protocol The VHRD technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exists in durations of 5,15 and 30 minutes.

In the group VHRD 1 and 2, the investigators use the program throughout the regional block. The duration chosen for the VHRD program was 15 or 30 min depending of the time required for the regional procedure.

In the group VHRD 2, the investigators use the program of 5 min for the session occuring before the regional procedure, followed by a 15 or 30 min program during the regional procedure.

Patients were coached by a separate practitioner aside from the regional anesthesiologist performing the regional block.

Study Outcomes The first endpoint consist in a significant minimal decrease of 50% of the requirement of IVS (opioids (µg) and benzodiazepine (mg)) delivered to the patient throughout the regional performance, in comparison to the IVS group when using VRHD.

The second endpoint is to determine if the VRHD increases the patient's satisfaction of their anaesthetic management.

The third endpoint is to study various parameters of this specific anesthetic management: time required for the use and installation of the VRHD device; variation of hemodynamic parameters between the separate groups, pain procedure-related and behavioural pain scale scores between the separate groups;

Statistical Analysis As the first endpoint is to determine if the VRHD decreases the need of pharmacologic intravenous sedation of 50%, the sample size (N=60) is determined by an intention-to-treat test (control group n=20, VRHD 1 n= 20 and VRHD n= 20).

Conditions
Anesthesia
Being tested
OncomfortTM device
Keywords
regional anesthesia, virtual reality, hypnosis, distraction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OncomfortTM deviceDevice

    The VHRD (Virtual Reality Hypnosis Distraction) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes

Study groups in NCT04024904
Study groupRoleWhat they receive
control groupNo interventionIn the control group, the patient received the standard pharmacologic intravenous sedation before the regional anaesthesia (2 mg midazolam + 5 µg de sufentanil) without VRHD (Virtual Reality Hypnosis Distraction).
VRHD1ExperimentalIn the study group VRHD (Virtual Reality Hypnosis Distraction) 1, the patient received the VHRD technique during the peripheral nerve block and received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score >3).
Receives: Device: OncomfortTM device
VRHD2ExperimentalIn the study group VRHD (Virtual Reality Hypnosis Distraction) 2, the patient received the VHRD technique for the first time before the regional procedure and a second time during the peripheral nerve block. The patient received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score >3).
Receives: Device: OncomfortTM device

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of patients receiving pharmacological sedation

    Collecting the proportion of patients (n) receiving pharmacological sedation as opioids (micrograms) and benzodiazepine (milligrams) from the beginning to the end of the regional procedure.

    Measured: immediately after the regional procedure

Secondary outcomes (1)
  1. patient's satisfaction with visual analogue scale(VAS) (a range of scores from 0-10)

    The patient's satisfaction score is determined by measuring the distance (cm) on the 10 cm line between the "no satisfaction" anchor and the patient's mark, providing a range of scores from 0-10. A higher score indicates greater satisfaction. Based on the distribution of satisfaction VAS scores during the regional procedure who described their satisfaction as none, moderate or very good, the following cut points on the satisfaction VAS have been decided: no satisfaction (0-4cm), moderate satisfaction (4,1-7 cm), and very satisfaction (7,1-10 cm).

    Measured: immediately after regional procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jul 2019
  2. Study start26 Jul 2018
  3. Primary completion30 Nov 2018
  4. Study completion30 Nov 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
The Virtual Hypnosis Reality Distraction (VHRD) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes. In the group VHRD 1 and 2 we use the program throughout the regional block. The time choose for the VHRD program is 15 or 30 min depending of the time required for the regional procedure. In the group VHRD 2, we use the program of 5 min and we applied the device before the regional procedure.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04024904
Sponsor's protocol ID
B406201836302
Status last verified
Jan 2022
First submitted
18 Apr 2019
Last updated
18 Jan 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Hu P, Harmon D, Frizelle H. Patient comfort during regional anesthesia. J Clin Anesth. 2007 Feb;19(1):67-74. doi: 10.1016/j.jclinane.2006.02.016.

    PubMed 17321932
  • Hoffman HG, Seibel EJ, Richards TL, Furness TA, Patterson DR, Sharar SR. Virtual reality helmet display quality influences the magnitude of virtual reality analgesia. J Pain. 2006 Nov;7(11):843-50. doi: 10.1016/j.jpain.2006.04.006.

    PubMed 17074626
  • Pandya PG, Kim TE, Howard SK, Stary E, Leng JC, Hunter OO, Mariano ER. Virtual reality distraction decreases routine intravenous sedation and procedure-related pain during preoperative adductor canal catheter insertion: a retrospective study. Korean J Anesthesiol. 2017 Aug;70(4):439-445. doi: 10.4097/kjae.2017.70.4.439. Epub 2017 Mar 15.

    PubMed 28794840
  • Mulier JP. Perioperative opioids aggravate obstructive breathing in sleep apnea syndrome: mechanisms and alternative anesthesia strategies. Curr Opin Anaesthesiol. 2016 Feb;29(1):129-33. doi: 10.1097/ACO.0000000000000281.

    PubMed 26595546
  • Guenther U, Riedel L, Radtke FM. Patients prone for postoperative delirium: preoperative assessment, perioperative prophylaxis, postoperative treatment. Curr Opin Anaesthesiol. 2016 Jun;29(3):384-90. doi: 10.1097/ACO.0000000000000327.

    PubMed 26905874
  • Wobst AH. Hypnosis and surgery: past, present, and future. Anesth Analg. 2007 May;104(5):1199-208. doi: 10.1213/01.ane.0000260616.49050.6d.

    PubMed 17456675
  • Hauser W, Hagl M, Schmierer A, Hansen E. The Efficacy, Safety and Applications of Medical Hypnosis. Dtsch Arztebl Int. 2016 Apr 29;113(17):289-96. doi: 10.3238/arztebl.2016.0289.

    PubMed 27173407
  • Askay SW, Patterson DR, Sharar SR. VIRTUAL REALITY HYPNOSIS. Contemp Hypn. 2009 Mar;26(1):40-47. doi: 10.1002/ch.371.

    PubMed 20737029
  • Malloy KM, Milling LS. The effectiveness of virtual reality distraction for pain reduction: a systematic review. Clin Psychol Rev. 2010 Dec;30(8):1011-8. doi: 10.1016/j.cpr.2010.07.001. Epub 2010 Jul 13.

    PubMed 20691523
  • Li A, Montano Z, Chen VJ, Gold JI. Virtual reality and pain management: current trends and future directions. Pain Manag. 2011 Mar;1(2):147-157. doi: 10.2217/pmt.10.15.

    PubMed 21779307
  • Tashjian VC, Mosadeghi S, Howard AR, Lopez M, Dupuy T, Reid M, Martinez B, Ahmed S, Dailey F, Robbins K, Rosen B, Fuller G, Danovitch I, IsHak W, Spiegel B. Virtual Reality for Management of Pain in Hospitalized Patients: Results of a Controlled Trial. JMIR Ment Health. 2017 Mar 29;4(1):e9. doi: 10.2196/mental.7387.

    PubMed 28356241
  • Mahrer NE, Gold JI. The use of virtual reality for pain control: a review. Curr Pain Headache Rep. 2009 Apr;13(2):100-9. doi: 10.1007/s11916-009-0019-8.

    PubMed 19272275
  • Carrougher GJ, Hoffman HG, Nakamura D, Lezotte D, Soltani M, Leahy L, Engrav LH, Patterson DR. The effect of virtual reality on pain and range of motion in adults with burn injuries. J Burn Care Res. 2009 Sep-Oct;30(5):785-91. doi: 10.1097/BCR.0b013e3181b485d3.

    PubMed 19692911
  • Furman E, Jasinevicius TR, Bissada NF, Victoroff KZ, Skillicorn R, Buchner M. Virtual reality distraction for pain control during periodontal scaling and root planing procedures. J Am Dent Assoc. 2009 Dec;140(12):1508-16. doi: 10.14219/jada.archive.2009.0102.

    PubMed 19955069
  • Gold JI, Kim SH, Kant AJ, Joseph MH, Rizzo AS. Effectiveness of virtual reality for pediatric pain distraction during i.v. placement. Cyberpsychol Behav. 2006 Apr;9(2):207-12. doi: 10.1089/cpb.2006.9.207.

    PubMed 16640481

Questions about this trial

What is this clinical trial studying?

A study testing OncomfortTM device in people with Anesthesia, run by Erasme University Hospital at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Jan 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of patients receiving pharmacological sedation (time frame: immediately after the regional procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04024904, which also lists 17 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in